137 related articles for article (PubMed ID: 16093975)
21. Detailed marker chromosome analysis in cell line U-BLC1, established from transitional-cell carcinoma of the bladder.
Bruch J; Wöhr G; Brüderlein S; Barbi G; Wolter H; Dixkens C; Mattfeldt T; Möller P; Paiss T; Hautmann R; Vogel W; Hameister H
Int J Cancer; 1999 Mar; 80(6):903-10. PubMed ID: 10074925
[TBL] [Abstract][Full Text] [Related]
22. Overexpression of cyclooxygenase-2 (COX-2) in the mouse urinary bladder induces the expression of immune- and cell proliferation-related genes.
Wang X; Colby JK; Rengel RC; Fischer SM; Clinton SK; Klein RD
Mol Carcinog; 2009 Jan; 48(1):1-13. PubMed ID: 18444251
[TBL] [Abstract][Full Text] [Related]
23. Activation of RAS family genes in urothelial carcinoma.
Boulalas I; Zaravinos A; Karyotis I; Delakas D; Spandidos DA
J Urol; 2009 May; 181(5):2312-9. PubMed ID: 19303097
[TBL] [Abstract][Full Text] [Related]
24. Cytogenetic evidence of gene amplification in urothelial cancer--a possible mechanism of tumor invasiveness.
Milasin J; Mićić S
Urol Int; 1992; 48(3):258-60. PubMed ID: 1589912
[TBL] [Abstract][Full Text] [Related]
25. c-erbB-2 amplification and identical p53 mutations in concomitant transitional carcinomas of renal pelvis and urinary bladder.
Lunec J; Challen C; Wright C; Mellon K; Neal DE
Lancet; 1992 Feb; 339(8790):439-40. PubMed ID: 1346710
[No Abstract] [Full Text] [Related]
26. [Identification of gene expression patterns in superficial and invasive human bladder cancers].
Zhou L; Shi BT; Wang SX; Luo Y; Yang L; Zhang LL; Wang XY; He DL
Zhonghua Yi Xue Za Zhi; 2007 Mar; 87(12):798-801. PubMed ID: 17565857
[TBL] [Abstract][Full Text] [Related]
27. [In vitro and in vivo evaluation of inhibitory nucleic acid constructs for specific therapy of human urinary bladder carcinoma].
Kunze D; Füssel S; Meye A; Wuttig D; Krämer K; Kotzsch M; Toma M; Schwenzer B; Kausch I; Jocham D; Hakenberg OW; Grimm MO; Wirth MP
Urologe A; 2007 Sep; 46(9):1289. PubMed ID: 17665160
[No Abstract] [Full Text] [Related]
28. Prognostic significance of homozygous deletions and multiple duplications at the CDKN2A (p16INK4a)/ARF (p14ARF) locus in urinary bladder cancer.
Berggren de Verdier PJ; Kumar R; Adolfsson J; Larsson P; Norming U; Onelöv E; Wijkström H; Steineck G; Hemminki K
Scand J Urol Nephrol; 2006; 40(5):363-9. PubMed ID: 17060081
[TBL] [Abstract][Full Text] [Related]
29. Molecular genetics of human bladder carcinomas.
Perucca D; Szepetowski P; Simon MP; Gaudray P
Cancer Genet Cytogenet; 1990 Oct; 49(2):143-56. PubMed ID: 2208052
[TBL] [Abstract][Full Text] [Related]
30. Molecular determinants of outcome in bladder cancer.
Cote RJ; Chatterjee SJ
Cancer J Sci Am; 1999; 5(1):2-15. PubMed ID: 10188054
[No Abstract] [Full Text] [Related]
31. Pathways of development and progression in bladder cancer: new correlations between clinical observations and molecular mechanisms.
Jones PA; Droller MJ
Semin Urol; 1993 Nov; 11(4):177-92. PubMed ID: 8290824
[No Abstract] [Full Text] [Related]
32. Transitional cell carcinomas and nonurothelial carcinomas of the urinary bladder differ in the promoter methylation status of the caveolin-1, hDAB2IP and p53 genes, but not in the global methylation of Alu elements.
Kunze E; Von Bonin F; Werner C; Wendt M; Schlott T
Int J Mol Med; 2006 Jan; 17(1):3-13. PubMed ID: 16328005
[TBL] [Abstract][Full Text] [Related]
33. Overexpression of normal and mutated forms of HRAS induces orthotopic bladder invasion in a human transitional cell carcinoma.
Theodorescu D; Cornil I; Fernandez BJ; Kerbel RS
Proc Natl Acad Sci U S A; 1990 Nov; 87(22):9047-51. PubMed ID: 2247480
[TBL] [Abstract][Full Text] [Related]
34. Genetic alterations in bladder cancer and their clinical applications in molecular tumor staging.
Sugano K; Kakizoe T
Nat Clin Pract Urol; 2006 Dec; 3(12):642-52. PubMed ID: 17149381
[TBL] [Abstract][Full Text] [Related]
35. Clear cell carcinoma of the urinary bladder.
Lum D
Pathology; 2006 Aug; 38(4):367-70. PubMed ID: 16916733
[No Abstract] [Full Text] [Related]
36. Transient receptor potential vanilloid type 2 (TRPV2) expression in normal urothelium and in urothelial carcinoma of human bladder: correlation with the pathologic stage.
Caprodossi S; Lucciarini R; Amantini C; Nabissi M; Canesin G; Ballarini P; Di Spilimbergo A; Cardarelli MA; Servi L; Mammana G; Santoni G
Eur Urol; 2008 Sep; 54(3):612-20. PubMed ID: 17977643
[TBL] [Abstract][Full Text] [Related]
37. Lack of association between HLA-E polymorphisms and transitional cell carcinoma of the bladder.
Veiga-Castelli LC; de Paula Cruz AS; Inácio MM; Mendes-Junior CT; Vianello-Brondani R; Moreau P; Castelli EC; Donadi EA
Tissue Antigens; 2013 Sep; 82(3):197-200. PubMed ID: 23786553
[No Abstract] [Full Text] [Related]
38. [Detection of urothelial carcinoma of the urinary bladder by multicolor fluorescence in situ hybridization].
Zhang YG; Bi XG; Han YL; Cai Y; Xu X; Wu YP; Yang YL; Ma JH; Zhao P; Jia XM; Wang MR
Ai Zheng; 2007 Feb; 26(2):189-93. PubMed ID: 17298751
[TBL] [Abstract][Full Text] [Related]
39. FISH and genetics advance bladder-cancer diagnosis.
Hollenberg G
MLO Med Lab Obs; 2004 Jun; 36(6):26-7. PubMed ID: 15242179
[No Abstract] [Full Text] [Related]
40. Overexpression of HER-2/neu oncogene and transitional cell carcinoma of bladder.
Jalali Nadoushan MR; Taheri T; Jouian N; Zaeri F
Urol J; 2007; 4(3):151-4. PubMed ID: 17987577
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
